The missing link between chronic pain and depression


Friday, 04 October, 2019

The missing link between chronic pain and depression

Scientists at Hokkaido University have identified the brain mechanism linking chronic pain and depression in rats — a breakthrough that could potentially lead to the development of new treatments for both conditions. Their research has been published in The Journal of Neuroscience.

“Clinicians have known for a long time that chronic pain often leads to depression; however, the brain mechanism for this was unclear,” said Professor Masabumi Minami, a co-author on the paper.

The researchers looked at how neuronal pathways were affected by chronic pain in rats. They used an electrophysiological technique to measure the activities of neurons after four weeks of chronic pain.

They found that persistent pain caused changes in the neuronal pathway projecting from the brain region called bed nucleus of the stria terminalis (BNST) to the region called ventral tegmental area (VTA). Specifically, they found enhanced signalling mediated by corticotropin-releasing factor (CRF), which is a neuropeptide known to be involved in the negative emotions such as anxiety and fear, in the BNST of chronic pain animals.

Crucially, they showed that this enhanced CRF signalling leads to suppression of the brain reward system, the nervous system that is activated by rewards and related to production of pleasure and motivation. Suppression of the reward system is considered to be an underlying mechanism of depression, which leads to decreased pleasure and motivation.

“By clarifying the mechanism by which the brain reward system is continuously suppressed, we found the missing link between chronic pain and depression,” said Prof Minami.

The researchers found that when they treated the rats with a drug that blocked the excessive CRF signals, the activity of dopamine neurons, which play an important role in the brain reward system, was increased. This suggests that drugs targeting neuropeptides such as CRF could be developed in order to treat chronic pain and depression in the future.

“These findings could not only lead to improved treatment of emotional aspect of chronic pain, but also to new therapeutics for depressive disorders,” said Prof Minami.

Image credit: ©stock.adobe.com/au/John Gomez

Please follow us and share on Twitter and Facebook. You can also subscribe for FREE to our weekly newsletters and bimonthly magazine.

Related News

Repurposed drugs show promise in heart muscle regeneration

The FDA-approved medications, when given in combination, target two proteins that regulate the...

A pre-emptive approach to treating leukaemia relapse

The monitoring of measurable residual disease (MRD), medication and low-dose chemotherapy is...

Long COVID abnormalities appear to resolve over time

Researchers at UNSW's Kirby Institute have shown that biomarkers in long COVID patients have...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd